Haya Taitel
Direttore/Membro del Consiglio presso ENTERA BIO LTD.
Patrimonio netto: 40 500 $ in data 31/05/2024
Profilo
Haya Taitel is an Independent Director at Entera Bio Ltd.
since 2023.
Previously, she worked as the Chief Commercial Officer at Kadmon Holdings, Inc. from 2018 to 2021.
She completed her undergraduate degree at The Hebrew University of Jerusalem and her graduate degree at Temple University School of Pharmacy.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ENTERA BIO LTD.
0.05% | 23/05/2024 | 18 000 ( 0.05% ) | 40 500 $ | 31/05/2024 |
Posizioni attive di Haya Taitel
Società | Posizione | Inizio |
---|---|---|
ENTERA BIO LTD. | Direttore/Membro del Consiglio | 07/06/2023 |
Precedenti posizioni note di Haya Taitel
Società | Posizione | Fine |
---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01/11/2021 |
Formazione di Haya Taitel
Temple University School of Pharmacy | Graduate Degree |
The Hebrew University of Jerusalem | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ENTERA BIO LTD. | Health Technology |
Aziende private | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Haya Taitel